biotech · Type 1 Diabetes Mellitus · Dehydration · HALO
HALOZYME THERAPEUTICS
HALOZYME THERAPEUTICS, INC.
HALOZYME THERAPEUTICS patent portfolio — 70 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 12390 El Camino Real, San Diego, California 92130, US
- Founded
- 2021
- Employees
- 530
- Programs
- 45
- Drugs
- 33
- Patents
- 70
HALOZYME THERAPEUTICS patents
70 pharmaceutical patents indexed for HALOZYME THERAPEUTICS. 0 expire within 24 months.
HALOZYME THERAPEUTICS has 70 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 8927249
Extended soluble PH20 polypeptides and uses thereof
granted -
US 8846034
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
granted -
US 8815558
Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
granted -
US 8772246
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8765685
Methods for treating edema by administering a Soluble Hyaluronidase Glycoprotein (sHASEGP)
granted -
US 8580252
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
granted -
US 8568713
Super fast-acting insulin compositions
granted -
US 8450470
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8431124
Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
granted -
US 8431380
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8318154
Super fast-acting insulin compositions
granted -
US 8257699
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
granted -
US 8202517
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 8105586
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
granted -
US 7871607
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
granted -
US 7846431
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
granted -
US 7829081
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
granted -
US 7786096
Inhibition of antigen presentation with poorly catabolized polymers
granted -
US 7767429
Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
granted -
US 7718428
Myeloid colony stimulating factor and uses thereof
granted -
US 7544499
Human chondroitinase glycoprotein (CHASEGP), process for preparing the same, and pharmaceutical compositions comprising thereof
granted -
US 7538097
Inhibition of antigen presentation with poorly catabolized polymers
granted
Frequently asked questions
How many patents does HALOZYME THERAPEUTICS have?
70 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do HALOZYME THERAPEUTICS patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.